343 results about "Respiratory mucus" patented technology

Sinusitis, enlarged nasal turbinates, tumors, infections, hearing disorders, allergic conditions, facial fractures and other disorders of the ear, nose and throat are diagnosed and/or treated using minimally invasive approaches and, in many cases, flexible catheters as opposed to instruments having rigid shafts. Various diagnostic procedures and devices are used to perform imaging studies, mucus flow studies, air/gas flow studies, anatomic dimension studies, endoscopic studies and transillumination studies. Access and occluder devices may be used to establish fluid tight seals in the anterior or posterior nasal cavities/nasopharynx and to facilitate insertion of working devices (e.g., scopes, guidewires, catheters, tissue cutting or remodeling devices, electrosurgical devices, energy emitting devices, devices for injecting diagnostic or therapeutic agents, devices for implanting devices such as stents, substance eluting devices, substance delivery implants, etc.

Sinusitis, mucocysts, tumors, infections, hearing disorders, choanal atresia, fractures and other disorders of the paranasal sinuses, Eustachian tubes, Lachrymal ducts and other ear, nose, throat and mouth structures are diagnosed and/or treated using minimally invasive approaches and, in many cases, flexible catheters as opposed to instruments having rigid shafts. Various diagnostic procedures and devices are used to perform imaging studies, mucus flow studies, air/gas flow studies, anatomic dimension studies and endoscopic studies. Access and occluding devices may be used to facilitate insertion of working devices such asendoscopes, wires, probes, needles, catheters, balloon catheters, dilation catheters, dilators, balloons, tissue cutting or remodeling devices, suction or irrigation devices, imaging devices, sizing devices, biopsy devices, image-guided devices containing sensors or transmitters, electrosurgical devices, energy emitting devices, devices for injecting diagnostic or therapeutic agents, devices for implanting devices such as stents, substance eluting or delivering devices and implants, etc.

A device and method for treating bodily conduits involves the application of energy to the smooth muscle tissue of the conduit walls to reduce the bulk of smooth muscle tissue and mucus glands. The irradiation treatment of the smooth muscle tissue causes a reduction in the amount of smooth muscle tissue over time which increases the inner diameter of the body conduit for improved fluid flow and prevents smooth muscle spasms. The treatment is particularly useful in the lungs for treatment of asthma to prevent bronchospasms, increase the airway diameter for improved air exchange, and reduce mucus secretions in the lungs.

A valve to perform lung volume reduction procedures is described. The valve is formed of a braided structure that is adapted for endoscopic insertion in a bronchial passage of a patient's lung. The braided structure has a proximal end and a distal end and is covered with a non porous coating adapted to prevent flow of air into the. A constricted portion of the braided structure is used to prevent flow of air through a central lumen of the structure, and to define at least one funnel shaped portion. The funnel shaped portion blocks the flow of air towards the constriction, i.e. towards the core of the lung. At least one hole is formed in the braided structure to permit flow of mucus from the distal end to the proximal end, to be expelled out of the lungs.

The present invention relates generally to the field of treatments for nasal congestion, and in particular, to a method and apparatus for alleviating nasal congestion in a patient by mechanically stimulating the sneezing reflex in the patient to urge drainage of the nasal passageways. The method includes inserting an instrument having a work tip portion provided with at least one filament into the nostril of the patient. The nasal mucosa of the patient is then probed with the at least one filament to stimulate in the patient the sneeze reflex. This probing action causes the patient to sneeze. With the patient's mouth closed, the sneeze urges at least one of mucus, fluid and debris in the nasal passages of the patient to be forcibly expelled through the nostrils of the patient thereby draining the nasal cavity of the patient. The instrument used in the performance of this method includes a handle portion upon which the work tip portion is carried. The handle portion may be integrally formed with the work tip portion or releasably attachable thereto. The instrument is further provided with a physical stop associated with one of the work tip portion and the handle portion to prevent injury resulting from the working tip portion being inserted too deeply into the nasal passages of the patient.

An active respiratory therapeutic device for clearing breathing passages, loosening and breaking up mucus plugs and phlegm in a patient's sinuses, trachea, bronchial passages and lungs while a patient is breathing normally through the device is disclosed. The apparatus preferably includes a C shaped curved hollow housing having a closed end portion and an open threaded end portion. The open end portion forms at least part of an acoustic coupling chamber. A generally funnel shaped tapered mouthpiece tapers to a small end portion sized to be inserted into a patient's mouth. The mouthpiece forms another part of the acoustic coupling chamber. An acoustic signal generator housed within the hollow housing generates and directs acoustic vibrations into and through the coupling chamber. The mouthpiece preferably includes a valve permitting a patient breathing through the mouthpiece to inhale through a valve opening and exhale through a bypass passage around the valve while at the same time coupling the acoustic coupling chamber into the patient's airways.

An endotracheal tube cleaning apparatus 10 which can be periodically inserted into the inside of an endotracheal tube 30 to shave away mucus deposits. In a preferred embodiment, this cleaning apparatus 10 comprises a flexible central tube 12 with an inflatable balloon 40 at its distal end. Affixed to the inflatable balloon are one or more shaving rings 70, each having a squared leading edge 72 to shave away mucus accumulations 60. In operation, the uninflated cleaning apparatus 10 of the present invention is inserted into the endotracheal tube until its distal end is properly aligned with or slightly beyond the distal end of the endotracheal tube. After proper alignment, the balloon 40 is inflated by a suitable inflation device, such as a syringe 14, until the balloon's shaving rings are pressed against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube and, in the process, the balloon's shaving rings shave off the mucus deposits from the inside of the endotracheal tube.

This relates to treating an asthmatic lung and more particularly, relates to advancing a treatment device into the lung and treating the lung with the device. This also includes additional steps of treating the airway wall, applying energy or heat to the airway wall in an asthmatic lung.

The present invention relates to devices used in the management of bodily airways including tracheostomy tubes, laryngectomy tubes, bronchial stents, bronchial Y-tubes, bronchial TY-tubes, and nasal stents. The devices may comprise a protective coating to prevent the accumulation of mucus, crusting and granulation on or around airway management devices, as well as prevent adhesion to tissues which can cause bleeding upon removal, and prevent build-up of blood, or blood clots, to the stent.

Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.

The invention relates to a cervical exfoliated cell preservative liquid, the preservative liquid comprises the following components with the contents (by weight): 20 percent to 50 percent of alcohols; 15 percent to 50 percent of anti-aggregation reagent; 5 percent to 10 percent of buffer solution; 1 percent to 20 percent of ion strength maintaining reagent; 0.01 percent to 0.5 percent of anti-microbial reagent; 0.1 to 5 percent of mucus dissolving reagent; and 0 to 0.5 percent of cleaning agent. Compared with the prior art, the preservative liquid can not only lead cells to maintain the shape in an in vitro liquid suspension environment, minimize the protein precipitation, dissolve larger protein substances, such as blood and mucus, and reduce the cell aggregation, but can also selectively eliminate or reduce red cells, effectively kill microbes, prevent the activity of reverse transcriptase and retain the integrity of nucleic acids and proteins for facilitating the later analysis; in addition, the preservative liquid can greatly reduce the costs of consumptive materials for the TCT detection, improve the sensitivity and the specificity of the cervical cancer screening and accelerate the promotion and the popularization of the TCT technology in a medical system.

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

Active multifunctional nanoparticles provide significant enhancement of the efficacy of model therapeutic and gene agents due to increased diffusion and penetration through mucus and biological barriers under the influence of a magnetic field.

Effervescent powders comprising inhalable particles are disclosed, as are methods for preparing these powders. The inhalable carrier particles comprise an inorganic or organic carbonate, and an acid, and exhibit effervescence when exposed to water or humid air. The particles have a mass median aerodynamic diameter suitable for nasal, bronchial, or pulmonary administration. The inhalable particles may be used as carriers for active agents. The inhalable particles may also be used to enhance permeability of mucosal and surface barriers on an inner surface of the nose, mouth, airway, and/or lungs of a patient, as well as to loosen, thin, cleanse, and remove mucus and extrinsic surface materials from an inner surface of the nose, mouth, airway, and/or lungs of a patient in need thereof.

A method of facilitating the obtaining of a mucus sample from at least one lung of a subject comprises administering to at least one lung of the subject, in an amount effective to hydrate lung mucous secretions and/or stimulate cilia beat frequency therein, uridine 5'-triphosphate, an active analog thereof, or a pharmaceutically acceptable salt of either thereof, and, optionally, concurrently administering to said at least one lung a physiologically acceptable salt in an amount effective to hydrate lung mucus secretions therein. A sputum or mucus sample is then collected from said at least one lung, which sample can then be analyzed for lung disease. Pharmaceutical compositions useful for carrying out the method comprise UTP or a salt thereof, alone or in combination with a physiologically acceptable salt, or a pharmaceutically acceptable salt of either thereof. The composition may be a liquid/liquid suspension composition or a dry powder composition.